DBDmitry Aleksandrovich Bakulin

Dmitry Aleksandrovich Bakulin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitry Aleksandrovich Bakulin has a total of 265 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunohistochemical analysis of Klotho protein expression in the cerebral cortex of aging rats with diabetes mellitus under pharmacological correction

    by Alexey V. Smirnov, Смирнов Алексей Владимирович, Aislu I. Dzhukeeva, Джукеева Айслу Ильнуровна, Vladislav E. Pustynnikov, Пустынников Владислав Эдуардович, Dmitry A. Bakulin, Бакулин Дмитрий Александрович, Yulia I. Velikorodnaya, Великородная Юлия Ивановна, et al.

    Diabetes mellitus leads to the development of vascular and cognitive impairment, which collectively leads to diabetic encephalopathy. Klotho protein (K), a critical regulator of aging and cognitive health, is considered a key link in the pathogenesis of diabetic encephalopathy. GABA derivatives are of particular interest in the search for neuroprotective strategies; however, their effect on Klotho expression in the context of diabetic brain damage remains poorly understood. The aim of the study: To study Klotho protein expression in the cerebral cortex of aging rats with diabetes mellitus and its pharmacological correction. Research methodology: A 6-month model of streptozotocin-induced diabetes mellitus was conducted in 36 Wistar albino rats (12 months old). Six months after the modeling of diabetes mellitus, the animals received succicard (50 mg/kg/day) or aminalon (1000 mg/kg/day) for one month. The area of immunoreactive material (anti-Klotho antibodies) in the retrosplenial cortex was measured using morphometry and Image J software. Statistical data processing was performed using ANOVA. The results of the research: Klotho protein expression in neurons and neuropil of the retrosplenial cortex was lower in animals with severe neurodegenerative disorders associated with diabetes mellitus than in healthy animals. These data suggest that Klotho protein deficiency plays a significant role in the development of diabetic encephalopathy in aging rats. In aging animals treated with the test compounds aminalon and succicard, Klotho protein expression was higher than in untreated rats. Conclusions: Analysis of pathological changes and Klotho protein expression in the cerebral cortex of aging rats with experimental streptozotocin-induced diabetes mellitus revealed a marked decrease in Klotho protein expression, even to the point of being absent, in the motor, primary somatosensory, and auditory cortex, as well as a less pronounced decrease in expression in the retrosplenial cortex. Pharmacological correction with aminalon and succicard demonstrated restoration of Klotho protein expression in the perikarya of neurons in the retrosplenial cortex. The results of the study suggest that the compounds studied may be effective in the treatment of diabetic encephalopathy.

  • Open Access

    Logistical parameters of goods as an object of optimization of warehouse accounting and operational processes

    by Elizaveta V. Pavlova, Павлова Елизавета Валерьевна, Denis V. Kurkin, Куркин Денис Владимирович, Yulia V. Gorbunova, Горбунова Юлия Васильевна, Olga V. Marincheva, Маринчева Ольга Викторовна, Dmitry A. Bakulin, Бакулин Дмитрий Александрович, et al.

    Introduction. Optimization of warehouse accounting and operational processes is an important area for improving the efficiency of pharmaceutical logistics. The aim of the study was to investigate operational processes and the warehouse accounting system for potential optimization. Materials and methods. The object of the study was the processes of managing the logistical parameters of goods at the pharmaceutical warehouse of FM Logistic JSC while servicing the International Committee of the Red Cross. Issues of management, economics, law, and digitalization Results. It was demonstrated that the transition from a paper-based information card to direct data entry using a handheld data terminal in the warehouse management system reduced the processing time per item from 5 min 49 s to 1 min 51 s, that is, by 68.2%. Discussion. The proposed approach may be applied in warehouses with a broad and dynamically changing assortment to improve the quality of master data management. Conclusion. Effective master data management makes it possible to improve subsequent warehouse processes, such as product slotting, generation of order picking tasks, calculation of the number, volume, and weight of cargo units, and transport planning for the delivery of prepared orders.

  • Original drug products approved by the Food and Drug Administration (Center for Drug Evaluation and Research) in 2025

    by D. V. Kurkin, N. A. Osadchenko, D. A. Galkina, D. A. Bakulin, Yu. G. Ustyakina, S. A. Voskresensky, A. R. Makarova, O. V. Shatalova, A. V. Strygin, V. I. Petrov, et al.

    The annual review of new drugs approved by the FDA is an important tool for analyzing current trends in pharmacology and medicine, reflecting progress in the treatment of complex diseases, including oncological pathologies, orphan diseases, and infectious processes. The article aims to inform medical specialists and pharmacologists about current trends in the development and registration of innovative medicinal products in 2025. The aim. To summarize and systematize data on the latest medicinal products launched in 2025, and to analyze their mechanisms of action. Materials and methods. The presented data are taken from open sources and supplemented by the results of individual studies aimed to the investigate new mechanisms and approaches in therapy. The main list of new medicines and introductory information about them are taken from the report of the Food and Drug Administration (FDA) — "Novel Drug Approvals for 2025. Results. In 2025, the FDA approved 46 drugs, of which 31 were small molecules and 15 were macromolecules. Among the drugs in the first group, 11 (24 % of all new drugs and 35 % of all new small molecules) are used in oncology, 2 are immunotropic, and 2 are for cardiology. The majority (16 drugs) belong to miscellaneous drug groups. Among biologicals, the largest portion consisted of monoclonal antibodies for the treatment of non-oncological diseases — 6 (13 % of all and 40 % of biologicals) and monoclonal antibodies for the treatment of oncological diseases — 5 (11 % of all and 33 % of biologicals). Nucleic acid-based drugs and protein molecules, excluding antibodies, accounted for 3 (7 % of all and 20 % of biologicals) and 1 (2 % of all and 7 % of biologicals) respectively. Conclusion. The significant proportion of biopharmaceuticals among newly registered drug products in 2025 highlights the dynamic development of the pharmaceutical industry and its focus on personalized medicine and biotechnology. Therapy based on mAbs interacting with receptors, as well as immunotherapy based on newly discovered mechanisms of anti-tumor immunity, occupies a substantial part of the structure of original drugs. The search for new rational antibiotic combinations remains relevant. Small molecules still constitute the largest share of the original drug market, among which drug substances — ligands of new targets and oligonucleotide sequences are emerging. This review is compiled for medical specialists and pharmacologists to familiarize them with current trends in the registration of original drugs and in the therapy of malignant neoplasms, as well as orphan diseases.

  • Open Access

    Effects of Collagen Hydrolysate-Based Protein Complexes on Physical Endurance, Glucose Metabolism, and Renal Function in Rats

    by Denis V. Kurkin, Dmitry A. Bakulin, Nazar A. Osadchenko, Natalia S. Murina, Elena V. Litvinova

    Background/Objectives: The increasing prevalence of nutrition-related diseases and the limited availability of convenient, metabolically safe, high-protein foods represent a pressing public health challenge. This study aimed to evaluate the effects of four composite animal-derived high-protein ingredients based on collagen enzymatic hydrolysates on physical endurance, feeding behaviour, carbohydrate metabolism, renal function, and behavioural parameters in rats. Methods: Four lyophilised collagen hydrolysate-based ingredients were developed using enzymatic biotransformation of bovine and porcine raw materials, combined with bovine whey protein concentrate, bovine meat trim hydrolysate, porcine blood plasma proteins, and an api-component (Samples 1–4; protein content 87–89%). Ninety male Wistar rats were randomised into one control group and four experimental groups (n = 20 per experimental group, n = 10 controls) and received test samples by intragastric gavage at 3000 mg/kg/day for 40 days. Physical endurance was assessed via a weighted forced swimming test (days 0, 30, and 40); behavioural status by open field, adhesive removal, and marble burying tests; and biochemical parameters (blood glucose, serum urea, creatinine, urinary protein, and GFR) at days 0 and 40. Results: All experimental groups demonstrated a significant reduction in standard chow consumption (19–24%, p < 0.01) without affecting body weight gain. Physical endurance improved significantly in all groups relative to baseline, with the most pronounced effect in the Sample 3 group (+39% at day 40, p < 0.05). Blood glucose levels were significantly reduced across all groups (9–16%, p < 0.05). No adverse behavioural effects were observed. Biochemical markers indicated an adaptive rather than pathological renal response, with elevated GFR in three of four experimental groups (p < 0.05) and reduced proteinuria in the Sample 1 and Sample 3 groups. Conclusions: Forty-day administration of collagen hydrolysate-based protein complexes improved physical endurance and glucose metabolism, reduced food intake without compromising body weight, and did not impair renal function or behavioural status in healthy adult rats. These findings support the potential of such ingredients as functional food components, pending confirmation of long-term safety in extended studies.

  • Open Access

    Effects of Collagen Hydrolysate-Based Protein Complexes on Physical Endurance, Glucose Metabolism, and Renal Function in Rats

    by Denis Kurkin, Dmitry Bakulin, Nazar Osadchenko, Natalia Murina, Elena V. Litvinova

    Background/Objectives: The increasing prevalence of nutrition-related diseases and the limited availability of convenient, metabolically safe, high-protein foods represent a pressing public health challenge. This study aimed to evaluate the effects of four composite animal-derived high-protein ingredients based on collagen enzymatic hydrolysates on physical endurance, feeding behaviour, carbohydrate metabolism, renal function, and behavioural parameters in rats. Methods: Four lyophilised collagen hydrolysate-based ingredients were developed using enzymatic biotransformation of bovine and porcine raw materials, combined with whey protein concentrate, bovine meat trim hydrolysate, blood plasma proteins, and an api-component (Samples 1–4; protein content 87–89%). Ninety male Wistar rats were randomised into one control group and four experimental groups (n = 20 per experimental group, n = 10 controls) and received test samples by intragastric gavage at 3000 mg/kg/day for 40 days. Physical endurance was assessed via a weighted forced swimming test (days 0, 30, and 40); behavioural status by open field, adhesive removal, and marble burying tests; and biochemical parameters (blood glucose, serum urea, creatinine, urinary protein, and GFR) at days 0 and 40. Results: All experimental groups demonstrated a significant reduction in standard chow consumption (19–24%, p < 0.01) without affecting body weight gain. Physical endurance improved significantly in all groups relative to baseline, with the most pronounced effect in the Sample 3 group (+39% at day 40, p < 0.05). Blood glucose levels were significantly reduced across all groups (9–16%, p < 0.05). No adverse behavioural effects were observed. Biochemical markers indicated an adaptive rather than pathological renal response, with elevated GFR in three of four experimental groups (p < 0.05) and reduced proteinuria in the Sample 1 and Sample 3 groups. Conclusions: Forty-day administration of collagen hydrolysate-based protein complexes improved physical endurance and glucose metabolism, reduced food intake without compromising body weight, and did not impair renal function or behavioural status in healthy adult rats. These findings support the potential of such ingredients as functional food components, pending confirmation of long-term safety in extended studies.

  • Metabolic effects of GABA derivatives and their combined use with sitagliptin in experimental obesity

    by I. N. Tyurenkov, D. A. Bakulin, A. A. Sokolova, A. V. Smirnov, A. I. Batsunov, N. S. Bolokhov, Yu. I. Velikorodnaya, O. S. Vasilyeva, S. V. Makarenko

    BACKGROUND : The increase in the number of people with obesity is associated with an increase in the prevalence of cardiovascular diseases, justifying the search for new drugs to correct metabolic disorders. AIM : To assess the metabolic effects of GABA derivatives (FPS and MFBA compositions) when used separately and in combination with sitagliptin in a model of carbohydrate metabolism disorder induced by alimentary obesity. MATERIALS AND METHODS : The study was conducted on male rats with alimentary obesity. Following a six-month high-fat, high-calorie diet, seven groups were formed (n=8), including a positive control group (intact rats without obesity) and a negative control group, as well as five groups with comparable obesity severity. These groups received the studied compositions separately for 30 days: MFBA (20 mg/kg) and FPS (50 mg/kg), the reference drug sitagliptin (10 mg/kg), and combinations of MFBA+sitagliptin (20+10 mg/kg), FPS+sitagliptin (50+10 mg/kg). Upon completion of the treatment course, changes in body weight, visceral fat mass, lipid profile, and severity of carbohydrate disorders based on the oral glucose tolerance test and the insulin tolerance test were assessed. Levels of glucagon, insulin, and glucagon-like peptide-1 (GLP-1) were determined by enzyme-linked immunosorbent assay. The degree of liver damage was evaluated based on levels of liver transaminases (ALT and AST) and through morphological examination of structural changes. RESULTS : It was established that the MFBA and FPS compositions, separately and in combination with sitagliptin, significantly reduced body weight and visceral fat mass, and enhanced the hypoglycemic action of sitagliptin (especially in combination with FPS). The separate and combined administration of MFBA and FPS with sitagliptin increased the levels of GLP-1 and insulin, improved glucose utilization, and increased insulin sensitivity, as well as normalized the lipid profile and levels of ALT, AST. Morphological examination revealed fewer foci of lymphoid infiltration and less pronounced fatty degeneration of the liver during treatment. The combination of FPS+sitagliptin showed the highest effectiveness. CONCLUSION : GABA derivatives - MFBA and FPS, in monotherapy and more pronouncedly in combination with sitagliptin, reduced the severity of metabolic disorders associated with obesity. The anorexigenic effect noted for the cyclic GABA derivative (FPS) and the ability to improve carbohydrate and lipid metabolism are of interest for further studies.

  • Psychotropic Activity of 4-Substituted Pyroglutamic Acids and Their Amides and Peptides

    by V. P. Krasnov, A. Yu. Vigorov, I. A. Nizova, D. A. Bakulin, D. D. Samarkin, I. N. Tyurenkov

  • Open Access

    Review of medicines approved by the Food and Drug Administration from 2012 to 2024

    by D. V. Kurkin, N. A. Osadchenko, D. A. Bakulin, E. I. Morkovin, S. A. Voskresenskiy, D. V. Maltsev, M. O. Maltseva, Yu. V. Gorbunova, O. V. Marincheva, V. I. Zvereva, et al.

    The aim . To describe the key characteristics of medical products approved by the Food and Drug Administration (FDA) and released by pharmaceutical companies from 2012 to 2024. Materials and methods. The analysis is based on data from FDA publications related to the approval of medical products from 2012 to 2024. The products were systematized by year, pathway and reason for approval, nature of the active substance (synthetic, semi-synthetic, natural or biological) and target disease (indication for use) in accordance with the codes of the Anatomical Therapeutic Chemical (ATC) classification. Results . During the analyzed period, the FDA approved a significant number of medicines, while maintaining a stable proportion of small molecules with a significant upward trend in the number of approved biologicals (monoclonal antibodies, CAR-T, siRNA, gene therapy, etc.). The largest proportion was accounted for by antitumor drugs and immunomodulators (group L according to ATC), demonstrating steady growth with projected growth in the future. Interest in drugs for the treatment of metabolic disorders and diseases of the nervous system remained steadily high, with the emergence of innovative therapeutic approaches. A gradual increase in the number of repositionings and extensions of indications was noted. The COVID-19 pandemic did not have a significant impact on the overall structure of approvals, and only two specific medicines for the treatment of COVID-19 were approved. There has been an increase in approvals for orphan diseases and the emergence of innovative therapeutic approaches: gene therapy, RNA interference, cell technologies, and bispecific antibodies. Conclusion. In the period from 2012 to 2024, the pharmaceutical industry has seen a fundamental shift towards biotechnological development methods, personalized medicine, and targeted therapy. During the period under review, the proportion of small molecule approvals remained fairly stable, but a steady (compared to previous periods) increase in the number of biotechnology product approvals (monoclonal antibodies, gene and RNA therapy) can be noted. The largest increase was noted in class L (antitumor drugs and immunomodulators), which reflects the focus of global pharmaceutical companies on the fundamental study and discovery of pharmacotherapy opportunities in the oncology and immunity. It is necessary to note the trend towards the development of drugs for the treatment of rare (orphan) diseases. In the field of therapy for metabolic disorders, during the specified period, drugs were approved that revolutionized understanding of an entire cluster of diseases and approaches to therapy, and a new standard of therapy was formed due to SGLT2 inhibitors and agonists of the incretin system receptors, including molecules with a multi-targeted effect. The COVID-19 pandemic led to a limited number of drug approvals for the treatment of this infection but thanks to it, the “door” to the development of new generation vaccines has been opened, which are largely fundamentally different from those currently existing. The discovery of new means to combat infectious agents of various nature (bacteria, protozoa, viruses, fungi, and parasites) is also one of the priority goals of pharmaceutical companies, as evidenced by a significant proportion of approvals of drugs with a similar effect. In terms of “reasons for registration,” the main share fell on original drugs; the contribution of new combinations and dosage forms was at its peak in the middle of the period and then decreased. Due to the expiration of patent protection for many drugs and the accumulation of data on their effects in the post-marketing period, a gradual increase in the number of repositionings and extensions of indications can be logically noted.


  • Open Access

    Immunohistochemical analysis of Klotho protein expression in the brain of aging rats with diabetes mellitus under pharmacological correction

    by Alexey V. Smirnov, Aislu I. Dzhukeeva, Ivan N. Tyurenkov, Maria R. Ekova, Vladislav E. Pustynnikov, Dmitry A. Bakulin, Nikita S. Bolokhov, Alexander A. Pokhlebin, Julia I. Velikorodnaya, Alexander I. Krayushkin, et al.

    The Klotho protein is one of the key regulators of aging and metabolism in the brain of aging rats. The relevance of the work is due to the high prevalence of diabetic encephalopathy in elderly people with diabetes and the lack of knowledge of the mechanisms of its correction. Materials and methods. Type 1 diabetes was modeled on 36 Wistar rats at the age of 12 months by administration of streptozotocin. After 6 months of hyperglycemia, the animals received aminalon (1000 mg/kg/day) or succicard (50 mg/kg /day) for 30 days. The expression of Klotho protein in the retrosplenic cortex, hippocampus, thalamus, and hypothalamus was evaluated by immunohistochemistry. Quantitative analysis was performed using the ImageJ program, statistical significance was determined using ANOVA. Results and discussion. In rats with DM without treatment, lower levels of IRM expression using polyclonal antibodies against the Klotho protein were detected in the retrosplenic cortex, hippocampus, thalamus and hypothalamus, which, in comparison with intact animals, indicates a possible dysfunction of neuronal metabolism and a decrease in the protective activity of the Klotho protein in conditions of diabetic neurodegeneration. During aminalon therapy, the expression level of Klotho was higher than in animals without therapy. During Succicard therapy, Klotho levels exceeded those of the untreated group, but were inferior to aminalon. Conclusions. When modeling diabetes mellitus (DM), a decrease in the expression of immunoreactive material was noted when using antibodies against the Klotho protein in the retrosplenic cortex, hippocampus, thalamus and hypothalamus of rats, which indicates the appearance of signs of premature aging in brain structures against the background of triggering neuroinflammation processes, which contributes to the development of diabetic enephalopathy. During aminalon therapy, the expression level of the Klotho protein increased significantly. Treatment with succicard diabetes contributed to a less pronounced increase in the level of Klotho protein expression compared with aminalon. The results of the study confirm the prospects of searching for a number of GABA derivatives in diabetes, taking into account metabolic disorders in the Klotho/FGF 23 signaling pathway (fibroblast growth factor 23, fibroblast growth factor 23) in key cerebral structures.

  • Comparative study of the neuroprotective effects of the drug Cytoflavin and citicoline in a rats model of hemorrhagic stroke

    by A.L. Kovalenko, A.YU. Petrov, G.A. Plisko, D.V. Kurkin, D.A. Bakulin, Yu.V. Gorbunova, N.O. Osadchenko, K.V. Lenskaya

    Objective. To compare the neuroprotective effects of Cytoflavine (CF) and citicoline (CC) in a rat model of hemorrhagic stroke (HS). Material and methods. The study was conducted on male Wistar rats. HS was induced by the injecting of autologous blood into brain tissue. Drugs CF and CC were administered in parenteral (10 days) and oral (25 days) forms. The experiment concluded with a 14-day post-treatment period. Neurological deficits were assessed after each treatment period, and brain tissue edema was measured immediately after the completion of both parenteral and oral treatments and again after 14 days of drug discontinuation. A series limited to a 10-day intravenous treatment with CF was created to compare the efficacy of single and combined treatment regimens. Results. HS stroke led to the development of significant neurological deficits. The greatest improvement was observed in the groups receiving oral treatments with CF and CC, which demonstrated pronounced neuroprotective effects and accelerated recovery of impaired functions, with some differences between the groups. The 10-day intravenous administration of CF and CC resulted in a comparable significant reduction in the severity of neurological deficits related to sensorimotor dysfunction. However, substantial recovery of cognitive function required continuation of oral treatment for 25 days. At the end of the oral treatment phase, edema severity in the affected hemisphere was comparable between both groups and significantly lower than in the placebo group. The therapeutic effect of CF (in terms of neurological deficit and brain tissue edema), in a combined administration regimen, persisted 14 days after discontinuation of treatment, in contrast to CC. In an additional series, where CF treatment was limited to a 10-day intravenous course, the anti-edema effect did not remain significant after the 14-day treatment cessation, with notable differences from the untreated group observed only in motor activity levels. Conclusion. The comparative study of the neuroprotective effects of CF and CC in a rat model of HS revealed that both drugs significantly reduced brain edema and neurological deficits related to sensorimotor and cognitive impairments. CC showed a slight psychostimulatory effect and a shorter duration of action after treatment cessation, while CF exhibited a longer-lasting effect on brain tissue edema, cognitive, and sensorimotor functions after discontinuation. The separate series with only 10-day intravenous CF administration was insufficient to achieve a stable therapeutic effect, suggesting that the continuation of CF treatment with oral forms is required to maintain long-term benefits in the context of experimental HS in rats.